Expression of specific antibodies against platelet glycoproteins in patients with mds and its significance.
- Author:
Juan-Dong WANG
1
;
Xiang-Lin PAN
;
Zhe YIN
;
Jun-Hua SUN
;
Gui-Xiang KONG
;
Ying-Jie CHEN
;
Cui-Ying JIANG
;
Ai-Xia DOU
;
Zhi-Lun WANG
Author Information
1. Department of Hematology, The Second Hospital of Shandong University, Jinan 250033, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antibodies;
immunology;
Antigens, Human Platelet;
immunology;
Autoantibodies;
biosynthesis;
immunology;
Female;
Humans;
Male;
Middle Aged;
Myelodysplastic Syndromes;
complications;
immunology;
Platelet Glycoprotein GPIIb-IIIa Complex;
immunology;
Platelet Glycoprotein GPIb-IX Complex;
immunology;
Thrombocytopenia;
etiology;
immunology
- From:
Journal of Experimental Hematology
2007;15(1):95-98
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to find platelet specific autoantibodies against glycoproteins in myelodysplastic syndrome (MDS) and to explore its role in pathogenesis of MDS. The plasma autoantibodies against GP IIb/IIIa and GP Ib/IX were measured by using a modified monoclonal antibody specific immobolization platelet antigens assay (MAIPA). Absorbance greater than mean value plus tripled standard deviation recorded from the normal controls were regarded as positive. The results indicated that the total positive rate in patients with MDS was 16.67% (5/30), the total positive rate in patients with ITP was 46.67% (14/30), the difference between MDS group and ITP group was significant (P < 0.05). It is concluded that partial patients with MDS have plasma specific autoantibodies against platelet GP II b/III a and GP Ib/IX, indicating correlation of thrombocytopenia of patients with immune factors and the autoantibody-mediated platelet destruction may be involved in the pathogenesis of MDS. It provides a new basis for immunosuppression therapy for MDS.
